GJB2-Related Hearing Loss: Preclinical Treatment Strategies Informed by Cx26 Structure and Variant Mechanisms
Background: Cx26 dysfunction and hearing loss
Connexin 26 (Cx26), encoded by GJB2, is a protein that helps cells exchange substances in the cochlea. A review published in the International Journal of Molecular Sciences synthesizes the protein’s structure and variant-specific disease mechanisms, and outlines preclinical treatment strategies and remaining challenges. Because the paper reviews prior literature, the findings it describes should be interpreted with each study’s subjects and outcome measures in mind.
According to the review, GJB2 variants account for up to 50% of autosomal recessive nonsyndromic hearing loss in some populations. This does not mean half of all people with hearing loss worldwide. Depending on the combination of inherited variants, the condition can range from congenital severe hearing loss to gradually progressive hearing decline.
Six Cx26 subunits assemble into a hemichannel, which joins a hemichannel in a neighboring cell to form a gap-junction channel made up of 12 subunits. In the cochlea, these channels help move ions, metabolites, and signaling molecules through networks that include supporting cells. Sensory hair cells are not directly connected to these gap junctions. Signaling and metabolic support from surrounding cells help sustain hair-cell development and function indirectly.
Key findings: channel loss and overactivity are distinct problems
The review classifies Cx26 dysfunction as loss of functional protein, impaired assembly or trafficking to the cell membrane, or abnormal channel gating. For example, c.35delG is a frameshift variant that alters the reading frame, leading to premature termination and production of a nonfunctional truncated protein. By contrast, some variants leave hemichannels abnormally open, causing excessive calcium influx and ATP efflux, resulting in cell damage. This is why an approach that uniformly increases channel activity may not suit every variant.
Structural studies also point to differences among regulatory factors. In a calcium-bound structure discussed in the review, the proposed model is that an electrical barrier limits cation movement rather than physically blocking the pore. Further validation is needed, however, to establish that the bound ion is calcium. Intracellular acidification is linked to pore occlusion associated with movement of the cytoplasmic region, while carbon dioxide is linked to pore constriction associated with changes in the N-terminal structure. The cytoplasmic region’s structure is not yet fully characterized, and the review notes uncertainty about how well structures obtained from purified protein reproduce the environment of an actual cell membrane.
The timing of dysfunction also matters for treatment strategy. In animal studies synthesized by the review, abnormalities in ATP and calcium signaling early in auditory development disrupted tissue maturation. In the mature cochlea, impaired potassium balance and metabolite supply contribute to hearing decline. This suggests that hearing loss is difficult to explain through impaired potassium recycling alone.
Implications and outlook: distinguish structural restoration from hearing recovery
The GJB2-targeted gene therapies covered in the review remain at the preclinical stage. Some mouse studies reported improved hearing after delivery of a normal gene using adeno-associated virus (AAV). In early studies, however, restoration of the gap-junction network and reduced cell death did not produce a significant improvement in hearing thresholds.
A base-editing study targeting the R75W variant reported correction of the variant in human cells and restoration of gap-junction structure in supporting cells of transgenic mice. These results do not provide a basis for calculating a rate of recovery to normal hearing. Antisense oligonucleotides that suppress variant transcripts and pharmacological chaperones that help proteins reach the cell membrane are also under study.
Clinical application still requires validation of delivery to target cells, treatment timing, durability of effects, and safety. Base editing in particular requires assessment of unintended editing at off-target sites and nearby bases, as well as effects from prolonged expression of the editing enzyme. No basis for translating developmental treatment windows in animals into a specific age in humans was identified in the supplied material. Cochlear implants are an established clinical management option, while therapies targeting the genetic cause remain at the research stage. The review points to future research that considers both variant function and cochlear developmental stage.
Source: Full review synthesizing Cx26 structure, variant mechanisms, and treatment prospects
Mutations in gap junction protein β-2 (GJB2), encoding Connexin 26 (Cx26), are the most common genetic cause of hearing loss, responsible for up to 50% of inherited non-syndromic cases worldwide. This review covers Cx26 from three perspectives: protein structure, mutant disease mechanisms, and treatment approaches. Structurally, 12 Cx26 subunits assemble into a gap junction channel connecting neighboring cells, enabling exchange of ions and signaling molecules; activity is regulated by calcium, pH, and CO
Research into treatments for GJB2-related hearing loss needs to distinguish the specific protein defect caused by a variant, beyond identifying the gene. For example, supplying a normal gene may be considered when functional protein is absent, while correction or suppression of variant expression may be explored for dominant-negative variants that also interfere with the function of normal protein. Simply increasing activity may be unsuitable when hemichannels are overactive. These distinctions help researchers choose cell and animal models and select outcome measures. They need to measure restoration of gap-junction structure separately from actual hearing improvement, and determine whether effects vary with treatment timing. This is guidance for preclinical study design; it does not mean patients can currently access personalized gene therapy. It can also help explain in clinical counseling how experimental approaches differ from current management, including cochlear implants.